A review of the lipid-related effects of fluvastatin

被引：34

作者：

Liberopoulos, EN

Daskalopoulou, SS

Mikhailidis, DP

Wierzbicki, AS

Elisaf, MS ^{[1
]}

机构：

[1] Univ Ioannina, Dept Internal Med, Sch Med, GR-45110 Ioannina, Greece

[2] St Thomas Hosp, Dept Chem Pathol, London, England

[3] UCL Royal Free & Univ Coll Med Sch, Dept Clin Biochem, Vasc Dis Prevent Clin, London, England

来源：

CURRENT MEDICAL RESEARCH AND OPINION | 2005年 / 21卷 / 02期

关键词：

cholesterol; fluvastatin; HIV; lipids; pleiotropic effects; renal function; statins;

D O I：

10.1185/030079905X26261

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Statin therapy has been shown to significantly decrease vascular events and overall mortality in primary and secondary prevention trials. This review considers the pharmacology, non-lipid-lowering effects and clinical trial evidence of fluvastatin based on a survey of PubMed entries. Findings: Recent clinical data show that treatment with fluvastatin is associated with a variety of benefits in different high-risk populations along with a good safety profile. Fluvastatin exerts non-lipid lowering-associated pleiotropic effects in both clinical and experimental studies. Furthermore, an extended-release formulation of fluvastatin with a favourable pharmacokinetic profile is available. Conclusion. Treatment with fluvastatin offers a convenient, safe and evidence-based approach to managing dyslipidaemias and preventing vascular events.

引用

页码：231 / 243

页数：13

共 169 条

[1]

ANDERSSEN SA, 2004, IN PRESS ATHEROSCLER

[2]

APPEL S, 1996, REV CONTEMP PHARMACO, V7, P167

[3]

Asberg Anders, 2004, Expert Rev Cardiovasc Ther, V2, P641, DOI 10.1586/14779072.2.5.641

[4] The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study [J].